Home Depot Inc vs Sana Biotechnology Inc — how do they compare? Home Depot Inc trades at $344.24 (market cap $353.46B), while Sana Biotechnology Inc trades at $3.8 (market cap $1.13B). The key difference: Home Depot Inc is far larger — about 312.8× Sana Biotechnology Inc's market cap, and Home Depot Inc pays a 2.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HD | SANA | |
|---|---|---|
Market Cap | $353.46B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $5.92 |
52-Week Low | $297.51 | $2.68 |
Enterprise Value | $415.01B | $1.05B |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $344.63, down 1.75% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. Revenue grew to $159.51 billion in 2025, though net margins have declined to 8.41%. The stock benefits from strong analyst support, with a consensus price target of $371.25, and a dividend payment scheduled for June 2026.
The stock presents a long-term opportunity driven by Pro customer growth and housing tailwinds, but faces risks from weakening big-ticket demand and margin pressures. With 59% of analysts rating it a buy, upside exists if earnings rebound, though high valuation multiples and economic sensitivity warrant caution.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Trailing returns across standard periods
Latest headlines on both assets
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →